Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
December 09, 2024 07:30 ET | Vor Biopharma
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
November 12, 2024 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
November 07, 2024 16:05 ET | Vor Biopharma
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
September 30, 2024 07:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new...
Vor-Wordmark-RGB-FullColor-070920.png
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
September 05, 2024 16:01 ET | Vor Biopharma
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
August 28, 2024 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
August 08, 2024 16:05 ET | Vor Biopharma
On-track for trem-cel + Mylotarg™ and VCAR33ALLO clinical updates in the second half of 2024 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024 16:01 ET | Vor Biopharma
CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 09, 2024 16:01 ET | Vor Biopharma
CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 1, 2024, the Compensation...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024 16:01 ET | Vor Biopharma
CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation...